Drug Trial Radar · NCT02145468
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Last checked: Nov 20, 2026Latest source record: Jun 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,503
Actual
Start
Jun 3, 2014
Primary completion
Dec 14, 2015
Study completion Dec 14, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- The TIMI Study Group
- First posted
- May 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack. There is a growing understanding that the inflammatory response to ACS is integral to the subsequent evolution of plaque instability. Losmapimod inhibits p38 mitogen activated protein kinase (MAPK), an enzyme which may play a central role in inflammation in the setting of heart attack. Inhibition of p38 MAPK may stabilize atherosclerotic plaques, reduce the risk of subsequent plaque rupture, indirectly improve vascular function and prevent subsequent thrombosis, and thus reduce infarct size and the risk of subsequent cardiac events. This study will test whether losmapimod can safely reduce the risk of a subsequent cardiovascular event (such as death, heart attack, or near heart attack requiring urgent treatment ) when started immediately after ACS (specifically, heart attack). Patients who present with heart attack and qualify for the study will be randomly assigned to receive 3 months treatment with either losmapimod twice daily or placebo, which will be administered in addition to the usual standard of care therapies for heart attack. Following the in-hospital period, subjects will return for outpatient visits at 4 and 12 weeks, as well as a follow up visit at 24 weeks.
Conditions
- Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice dailyDrug
Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
Placebo twice dailyDrug
Subjects will receive placebo as film-coated, round, plain faced tablets.
Standard therapyDrug
Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12Time frame: Up to 12 weeks
Locations
341 sites in 34 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Cottonwood, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Mission Viejo, California
GSK Investigational Site
Monterey, California
GSK Investigational Site
Orange, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Littleton, Colorado
GSK Investigational Site
Daytona Beach, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Jacksonville Beach, Florida
GSK Investigational Site
Ocala, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
Tallahassee, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Vero Beach, Florida
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Rome, Georgia
GSK Investigational Site
Coeur d'Alene, Idaho
GSK Investigational Site
Aurora, Illinois
GSK Investigational Site
Elmhurst, Illinois
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Muncie, Indiana
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
West Des Moines, Iowa
GSK Investigational Site
Alexandria, Louisiana
GSK Investigational Site
Baton Rouge, Louisiana
GSK Investigational Site
Slidell, Louisiana
GSK Investigational Site
Zachary, Louisiana
GSK Investigational Site
Auburn, Maine
GSK Investigational Site
Boston, Massachusetts
Showing 40 of 341 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.